Hansa Biopharma Ab Stock Analysis

HNSBF Stock  USD 2.93  0.00  0.00%   
Hansa Biopharma AB is undervalued with Real Value of 0.0 and Hype Value of 0.0. The main objective of Hansa Biopharma pink sheet analysis is to determine its intrinsic value, which is an estimate of what Hansa Biopharma AB is worth, separate from its market price. There are two main types of Hansa Biopharma's stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Hansa Biopharma's performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Hansa Biopharma's stock to identify patterns and trends that may indicate its future price movements.
The Hansa Biopharma pink sheet is traded in the USA on PINK Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Hansa Biopharma is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Hansa Pink Sheet trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Hansa Biopharma's ongoing operational relationships across important fundamental and technical indicators.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hansa Biopharma AB. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics.

Hansa Pink Sheet Analysis Notes

About 41.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 0.65. Hansa Biopharma AB had not issued any dividends in recent years. Hansa Biopharma AB , a biopharmaceutical company, develops immunomodulatory treatments for enabling transplants and rare immunoglobulin G -mediated autoimmune conditions, gene therapy, and cancer using its proprietary enzyme technology platform. Hansa Biopharma AB was incorporated in 2007 and is headquartered in Lund, Sweden. Hansa Medical is traded on OTC Exchange in the United States.The quote for Hansa Biopharma AB is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. To learn more about Hansa Biopharma AB call Goran Arvidson at 46 46 16 56 70 or check out https://www.hansabiopharma.com.

Hansa Biopharma AB Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more pink sheets at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Hansa Biopharma's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Hansa Biopharma AB or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Hansa Biopharma AB had very high historical volatility over the last 90 days
The company reported the revenue of 33.88 M. Net Loss for the year was (548.28 M) with profit before overhead, payroll, taxes, and interest of 116.05 M.
Hansa Biopharma AB has accumulated about 60.15 M in cash with (481.17 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.58.

Hansa Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 274.8 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Hansa Biopharma's market, we take the total number of its shares issued and multiply it by Hansa Biopharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Technical Drivers

As of the 28th of March, Hansa Biopharma retains the Market Risk Adjusted Performance of 0.7972, standard deviation of 4.03, and Risk Adjusted Performance of 0.0764. Hansa Biopharma technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Simply put, you can use this information to find out if the firm will indeed mirror its model of historical price patterns, or the prices will eventually revert. We have analyzed eleven technical drivers for Hansa Biopharma AB, which can be compared to its competitors. Please check out Hansa Biopharma AB variance and maximum drawdown to decide if Hansa Biopharma is priced fairly, providing market reflects its last-minute price of 2.93 per share. Please also validate Hansa Biopharma AB information ratio, which is currently at 0.0885 to confirm the company can sustain itself at a future point.

Hansa Biopharma AB Price Movement Analysis

Execute Study
The output start index for this execution was twenty-three with a total number of output elements of thirty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Hansa Biopharma middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Hansa Biopharma AB. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Hansa Biopharma Predictive Daily Indicators

Hansa Biopharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Hansa Biopharma pink sheet daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Hansa Biopharma Forecast Models

Hansa Biopharma's time-series forecasting models are one of many Hansa Biopharma's pink sheet analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Hansa Biopharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Hansa Pink Sheet Analysis

Pink Sheet analysis is the technique used by a trader or investor to examine and evaluate how Hansa Biopharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Hansa shares will generate the highest return on investment. We also built our pink sheet analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Pink Sheet such as Hansa Biopharma. By using and applying Hansa Pink Sheet analysis, traders can create a robust methodology for identifying Hansa entry and exit points for their positions.
Hansa Biopharma AB , a biopharmaceutical company, develops immunomodulatory treatments for enabling transplants and rare immunoglobulin G -mediated autoimmune conditions, gene therapy, and cancer using its proprietary enzyme technology platform. Hansa Biopharma AB was incorporated in 2007 and is headquartered in Lund, Sweden. Hansa Medical is traded on OTC Exchange in the United States.

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our pink sheet analysis tools, you can find out how much better you can do when adding Hansa Biopharma to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Equity Search Now

   

Equity Search

Search for actively traded equities including funds and ETFs from over 30 global markets
All  Next Launch Module
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hansa Biopharma AB. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics.
Note that the Hansa Biopharma AB information on this page should be used as a complementary analysis to other Hansa Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the AI Investment Finder module to use AI to screen and filter profitable investment opportunities.

Complementary Tools for Hansa Pink Sheet analysis

When running Hansa Biopharma's price analysis, check to measure Hansa Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hansa Biopharma is operating at the current time. Most of Hansa Biopharma's value examination focuses on studying past and present price action to predict the probability of Hansa Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hansa Biopharma's price. Additionally, you may evaluate how the addition of Hansa Biopharma to your portfolios can decrease your overall portfolio volatility.
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Please note, there is a significant difference between Hansa Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Hansa Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hansa Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.